about
Selective Estrogen Receptor ModulatorsDistant cancer effects on standardised testing of peripheral visionIn silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulatorsThe active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cellsSuggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.Protective effects of estrogen in a rat model of age-related cataracts.Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.Pharmacology and clinical applications of selective estrogen receptor modulators.Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms.Proliferative reactive gliosis is compatible with glial metabolic support and neuronal function.A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort studySelective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.Breast cancer medications and vision: effects of treatments for early-stage disease.Tamoxifen-associated vasculitis in a breast cancer patient.Ophthalmic Metastasis of Breast Cancer and Ocular Side Effects from Breast Cancer Treatment and Management: Mini ReviewCYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.Tamoxifen--the treatment of choice. Why look for alternatives?Conditional knockout of CTGF affects corneal wound healing.Dry eye syndrome in aromatase inhibitor users.Sinus involvement in breast cancer: case report.Metastases to nasal cavity and paranasal sinuses.Hydroxychloroquine retinopathy.Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells.Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review.Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration.Investigation and management of patients at high risk of developing cancer.Eye problems in breast cancer patients treated with tamoxifen.Characteristics of corneal phospholipidosis induced by topical ocular application of chloroquine and amiodarone in rabbitsMaculopathy following extended usage of Clomiphene citrate.Should we discontinue tamoxifen in a patient with vision-threatening ocular toxicity related to low-dose tamoxifen therapy?Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.Ocular findings in breast cancer patients using tamoxifen.To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity.The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptors.
P2860
Q26738923-29B0C2F7-6C95-48CC-B58F-AB2E0FCDBA31Q28353973-0B666C00-23B5-44F2-8DCD-847FF15ABE51Q28471679-D373A93A-7A05-4B27-B7EA-41B167EBB57FQ28546094-F861FF8F-3782-4A55-B79B-CC8C61B88B09Q30437854-7126292B-9154-4F3B-A883-577B546CC46EQ30748551-CBBC51AB-EBEC-4407-988C-7632B11C71C6Q33270673-D8ACD5D6-12E8-41F5-BF9A-C6F13430DBA6Q33384192-B9B0CBF1-71F6-47FE-93EC-A416FF9324D1Q34003273-911A3C6C-FA43-421D-8A1B-EEF825FC895AQ34045171-932DE50C-AE48-42C3-B65A-34A8F80FE227Q34252972-6C4D5DCD-38F1-479F-A946-DF179F6AEBEEQ34326845-D27742F0-03F0-480A-BFB9-CBDFC24C35BAQ35496778-1CF369B5-D7AC-4935-BD4B-1B3F8750155EQ35613567-2AAE87B2-6412-4076-AE4F-92CAC5F8A080Q35640600-09168B80-FAF4-460E-97F3-27B327B88B78Q36109257-9A0E188B-519E-4DE4-BDE7-736D6299CDDFQ36114445-761AA099-A31B-40FD-9F62-CA5FAD3F50BEQ37682622-CA8CB35C-7A52-4C83-B1D2-3A73340B1D9DQ38041583-BFB3419C-F2DB-4B37-80AD-EE1F0B0DD8D5Q38092228-79D85976-31BE-4D6F-92F0-4266630089FBQ38842833-26C64337-C359-4C6F-B400-F9F1AA3BFE02Q39172826-3FBAB796-61A8-4ADF-9879-BC5EA4E382E6Q40690857-BE5C2781-722B-4DE0-B021-6136CDDAE41DQ41488063-64A6D79E-3F18-4E06-91A1-BA781E197D48Q41700375-A4D8D801-C6D0-4608-B2F5-5054C927BFBFQ41735506-7F5753B7-D751-44B5-BDB8-5352D5DBEB2CQ41740407-A7A29556-94D9-4E28-97C9-41DC74AC0A34Q41912816-46C62F6D-991E-4955-AA5B-58AC62E646FFQ42905118-FF2A41D8-E00F-46CD-BEEB-5DD269A05F22Q44364366-CF394250-B199-4702-84B2-46F9E6141A34Q46166289-F326F478-A73C-4601-B148-D72C96ABA3AAQ50224137-97343414-D6F7-47E8-8AC4-C3A6A5F20276Q52818818-E9C88DF7-2143-468E-97D5-15BE24713D96Q53608866-36C02A7A-616B-4870-92B6-7FBB7E2D32B4
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Tamoxifen-associated eye disease. A review.
@en
type
label
Tamoxifen-associated eye disease. A review.
@en
prefLabel
Tamoxifen-associated eye disease. A review.
@en
P1476
Tamoxifen-associated eye disease. A review.
@en
P2093
S G Nayfield
P304
P356
10.1200/JCO.1996.14.3.1018
P407
P577
1996-03-01T00:00:00Z